AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action

Hagens Berman Sobol Shapiro LLP notified Aardvark Therapeutics (NASDAQ: AARD) investors of a pending securities fraud class action tied to offering documents from the February 13, 2025 IPO. The complaint alleges ARD-101 was significantly less safe than represented, citing undisclosed reversible cardiac observations such as QRS prolongation at above-target doses during trials. AARD shares fell over 56% after the February 27, 2026 voluntary pause of the Phase 3 HERO trial, and dropped another 32.1% after the FDA placed a full clinical hold on ARD-101's IND on May 14, 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.